JP7789056B2 - Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態 - Google Patents

Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態

Info

Publication number
JP7789056B2
JP7789056B2 JP2023507579A JP2023507579A JP7789056B2 JP 7789056 B2 JP7789056 B2 JP 7789056B2 JP 2023507579 A JP2023507579 A JP 2023507579A JP 2023507579 A JP2023507579 A JP 2023507579A JP 7789056 B2 JP7789056 B2 JP 7789056B2
Authority
JP
Japan
Prior art keywords
compound
crystalline form
disease
crystalline
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023507579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536911A5 (https=
JP2023536911A (ja
Inventor
ウェルダブ，アズメーロム
コレイア，タエ・キム
ジェンキンス，エアリアル・ダイアン
リン，イーキン
リー，チャオミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2023536911A publication Critical patent/JP2023536911A/ja
Publication of JP2023536911A5 publication Critical patent/JP2023536911A5/ja
Application granted granted Critical
Publication of JP7789056B2 publication Critical patent/JP7789056B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2023507579A 2020-08-03 2021-08-03 Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態 Active JP7789056B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063060281P 2020-08-03 2020-08-03
US63/060,281 2020-08-03
PCT/US2021/044341 WO2022031701A1 (en) 2020-08-03 2021-08-03 Crystaline forms of an o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitor

Publications (3)

Publication Number Publication Date
JP2023536911A JP2023536911A (ja) 2023-08-30
JP2023536911A5 JP2023536911A5 (https=) 2024-08-13
JP7789056B2 true JP7789056B2 (ja) 2025-12-19

Family

ID=77640732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507579A Active JP7789056B2 (ja) 2020-08-03 2021-08-03 Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態

Country Status (18)

Country Link
US (1) US20230286972A1 (https=)
EP (1) EP4188925A1 (https=)
JP (1) JP7789056B2 (https=)
KR (1) KR20230061395A (https=)
CN (1) CN116917284A (https=)
AR (1) AR123132A1 (https=)
AU (1) AU2021322186A1 (https=)
BR (1) BR112023002013A2 (https=)
CA (1) CA3188250A1 (https=)
CL (1) CL2023000327A1 (https=)
CO (1) CO2023002543A2 (https=)
CR (1) CR20230118A (https=)
IL (1) IL300365A (https=)
MX (1) MX2023001469A (https=)
PE (1) PE20231168A1 (https=)
TW (1) TW202220984A (https=)
UY (1) UY39366A (https=)
WO (1) WO2022031701A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2602139B (en) * 2020-12-18 2024-07-24 Nexeon Ltd Electroactive materials for metal-ion batteries
WO2025184490A1 (en) 2024-03-01 2025-09-04 Biogen Ma Inc. N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503298A (ja) 2016-12-16 2020-01-30 ヤンセン ファーマシューティカ エヌ．ベー． 単環式ｏｇａ阻害剤化合物
JP2020504142A (ja) 2017-01-27 2020-02-06 イーライ リリー アンド カンパニー Ｏｇａ阻害剤としてのｎ−［４−フルオロ−５−［［（２ｓ，４ｓ）−２−メチル−４−［（５−メチル−１，２，４−オキサジアゾール−３−イル）メトキシ］−１−ピペリジル］メチル］チアゾール−２−イル］アセトアミド
JP2020509004A (ja) 2017-02-27 2020-03-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
WO2020061150A1 (en) 2018-09-19 2020-03-26 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503298A (ja) 2016-12-16 2020-01-30 ヤンセン ファーマシューティカ エヌ．ベー． 単環式ｏｇａ阻害剤化合物
JP2020504142A (ja) 2017-01-27 2020-02-06 イーライ リリー アンド カンパニー Ｏｇａ阻害剤としてのｎ−［４−フルオロ−５−［［（２ｓ，４ｓ）−２−メチル−４−［（５−メチル−１，２，４−オキサジアゾール−３−イル）メトキシ］−１−ピペリジル］メチル］チアゾール−２−イル］アセトアミド
JP2020509004A (ja) 2017-02-27 2020-03-26 ヤンセン ファーマシューティカ エヌ．ベー． Ｏｇａ阻害剤としての、ピペリジン、モルホリンまたはピペラジンで置換されている［１，２，４］−トリアゾロ［１，５−ａ］−ピリミジニル誘導体
WO2020061150A1 (en) 2018-09-19 2020-03-26 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
平山令明，有機化合物結晶作製ハンドブック，2008年，p.17-23,37-40,45-51,57-65
芦澤一英，医薬品の多形現象と晶析の科学，2002年，pp.273,278,305-317

Also Published As

Publication number Publication date
TW202220984A (zh) 2022-06-01
CN116917284A (zh) 2023-10-20
PE20231168A1 (es) 2023-07-26
US20230286972A1 (en) 2023-09-14
AU2021322186A1 (en) 2023-04-06
BR112023002013A2 (pt) 2023-05-02
MX2023001469A (es) 2023-06-16
EP4188925A1 (en) 2023-06-07
CR20230118A (es) 2023-06-02
CA3188250A1 (en) 2022-02-10
CO2023002543A2 (es) 2023-06-09
UY39366A (es) 2022-02-25
CL2023000327A1 (es) 2023-10-06
JP2023536911A (ja) 2023-08-30
IL300365A (en) 2023-04-01
WO2022031701A1 (en) 2022-02-10
AR123132A1 (es) 2022-11-02
KR20230061395A (ko) 2023-05-08
WO2022031701A9 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
US10081625B2 (en) 5-methyl-1,2,4-oxadiazol-3-yl compounds
EP1912973B1 (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
EP1953151A1 (en) Salts of cynnamide compound or solvates thereof
JP7789056B2 (ja) Ｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤の結晶形態
US20250313564A1 (en) Acidic salt or crystal form of nitrogen-containing fused ring derivative inhibitor, and preparation method therefor and use thereof
TWI619719B (zh) 選擇性ｂａｃｅ１抑制劑
JP2020505367A (ja) 結晶形態の遊離塩基オキサジン誘導体
EA049044B1 (ru) Кристаллические формы ингибитора о-гликопротеин-2-ацетамидо-2-дезокси-3-d-глюкопиранозидазы
US11999726B2 (en) 5-methyl-4-fluoro-thiazol-2-yl compounds
JP7604387B2 (ja) ベンゾチアゾール化合物の薬学的塩、多形体及びその製造方法
HK40111611A (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
HK40111611B (zh) 含氮并环类衍生物抑制剂的酸式盐或晶型及其制备方法和应用
US20100317860A1 (en) Crystalline cinnamide compounds or salts thereof
HK40063558A (en) Pharmaceutical salts of benzothiazol compounds, polymorphs and methods for preparation thereof
NZ754849B2 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251209

R150 Certificate of patent or registration of utility model

Ref document number: 7789056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150